We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Envision (EVHC) Teams Up with Lyft to Focus on Transportation
Read MoreHide Full Article
Envision Healthcare Corporation , a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced that it has teamed up with on-demand transportation service provider Lyft. The duo will focus on providing non-emergency medical transportation services for patients.
Stock Performance
The price performance of Envision Healthcare was unfavorable in the last three months. The stock lost 1.45%, underperforming the Zacks classified Medical-Outpatient/ Home Care sub-industry’s gain of almost 4.98%.
Also, the estimate revision trend for the current year has been unfavorable. Two estimates moved south in the last two months against no movement in the opposite direction. This justifies the stock’s Zacks Rank #4 (Sell).
Partnership Details
Coming back to the news, we believe Envision Healthcare’s subsidiary American Medical Response (“AMR”) which is one of the largest domestic provider of medical transportation would benefit greatly from this partnership. The scope of the partnership would include technology integration and operations in 42 states where AMR operates. The partnership would also support AMR’s “One Call” service for the health care systems’ integrated patient transport programs.
Headquartered in Greenwood Village, CO, Envision Healthcare is a leading provider of physician-led services, ambulatory surgery services, post-acute care and medical transportation. Physician-led services are provided at more than 780 hospitals in 45 states and the District of Columbia. The company owns and operates 260 surgery centers and one surgical hospital in 35 states and the District of Columbia.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.
IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an 97.5% over the last one year.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Envision (EVHC) Teams Up with Lyft to Focus on Transportation
Envision Healthcare Corporation , a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced that it has teamed up with on-demand transportation service provider Lyft. The duo will focus on providing non-emergency medical transportation services for patients.
Stock Performance
The price performance of Envision Healthcare was unfavorable in the last three months. The stock lost 1.45%, underperforming the Zacks classified Medical-Outpatient/ Home Care sub-industry’s gain of almost 4.98%.
Also, the estimate revision trend for the current year has been unfavorable. Two estimates moved south in the last two months against no movement in the opposite direction. This justifies the stock’s Zacks Rank #4 (Sell).
Partnership Details
Coming back to the news, we believe Envision Healthcare’s subsidiary American Medical Response (“AMR”) which is one of the largest domestic provider of medical transportation would benefit greatly from this partnership. The scope of the partnership would include technology integration and operations in 42 states where AMR operates. The partnership would also support AMR’s “One Call” service for the health care systems’ integrated patient transport programs.
Headquartered in Greenwood Village, CO, Envision Healthcare is a leading provider of physician-led services, ambulatory surgery services, post-acute care and medical transportation. Physician-led services are provided at more than 780 hospitals in 45 states and the District of Columbia. The company owns and operates 260 surgery centers and one surgical hospital in 35 states and the District of Columbia.
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Fluidigm Corporation . Notably, Inogen and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy) while Fluidigm carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock registered an impressive one-year return of 70.6%.
IDEXX Laboratories has a long-term expected earnings growth rate of 15.04%. Additionally, the stock returned an 97.5% over the last one year.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock delivered a positive earnings surprise of 1.6% last quarter.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>